{"doi":"10.1016/j.clml.2022.11.006","title":"Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India.","abstract":null,"journal":"Clinical Lymphoma Myeloma and Leukemia","year":2023,"id":593722,"datarank":0.29188652235829704,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"self_citation_contribution":0.29188652235829704,"citation_network_contribution":0.0,"self_endowment_contribution":0.29188652235829704,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":351010,"name":"Reema Singh","orcid":"0000-0002-8658-7468","position":1,"is_corresponding":false},{"id":1519661,"name":"Jyotsna Kapoor","orcid":null,"position":2,"is_corresponding":false},{"id":1519662,"name":"Pritish Chandra Patra","orcid":null,"position":3,"is_corresponding":false},{"id":1519663,"name":"Narendra Agrawal","orcid":null,"position":4,"is_corresponding":false},{"id":1519664,"name":"Dinesh Bhurani","orcid":null,"position":5,"is_corresponding":false},{"id":1519665,"name":"Rohan Halder","orcid":"0000-0002-3100-558X","position":6,"is_corresponding":false},{"id":1519660,"name":"Rayaz Ahmed","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India.","abstract":"<h4>Background</h4>BCR-ABL Tyrosine kinase inhibitors (TKI's) are most successful of targeted therapies and are currently considered the cornerstone in the management of patients with chronic myeloid leukemia (CML). A recent study reported excellent outcomes of Dasatinib 50mg with better sustained response. Therefore, we aim to evaluate the molecular responses and safety of upfront Dasatinib 50mg in Indian CML-Chronic Phase patients.<h4>Methods</h4>It was an observational single-centre study. CML-CP patients started on Dasatinib 50mg daily were offered to participate in this study. Data of imatinib was collected retrospectively as a comparator group.<h4>Results</h4>Between June 2020 to Feb 2022, fifty patients were included in the dasatinib 50mg once daily group. Median age was 40 yrs. ranging from (19 to73) years. At a median follow up of 9.2 months, 49 patients completed three months treatment, out of which 48 patients were evaluated as one patient stopped medication after a month due to financial constraints. The response rate at three months for dasatinib 50mg daily and Imatinib were 68.75% and 69.7% respectively. At 12 months, 68% and 66.6% patients achieved major molecular response [MMR] in dasatinib 50mg and imatinib groups respectively.<h4>Conclusion</h4>In conclusion, low dose dasatinib is safe and effective as an upfront therapy in CML-CP. Early molecular response [EMR] rates were comparable in low dose dasatinib and imatinib arm but deep molecular responses were significantly higher in low dose dasatinib arm. Dasatinib, taken daily at a dose of 50mg, may offer a new, alternative choice as generic versions are available now for frontline therapy in CML-CP.","is_dataset_classified":null,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36566108","pmcid":null,"openalex_id":"https://openalex.org/W4309531150","authors":[],"funders":[{"funder_name":"Rajiv Gandhi Cancer Institute and Research Centre","grant_id":"","title":null}],"total_grants":1,"fwci":0.4735,"citation_percentile":0.66920683,"influential_citations":0,"citation_trend":[{"year":2024,"count":1},{"year":2025,"count":2},{"year":2026,"count":3}],"oa_status":"closed","license":"https://doi.org/10.15223/policy-004","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S2152265022017335?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2152265022017335?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.clml.2022.11.006","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36566108","host_type":"repository"}],"fields_of_study":["Chronic Myeloid Leukemia Treatments","Diverse Scientific Research Studies","Health, Education, and Cultural Studies","Adult","Humans","Antineoplastic Agents","Dasatinib","Imatinib Mesylate","India","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Leukemia, Myeloid, Chronic-Phase","Protein Kinase Inhibitors","Retrospective Studies","Treatment Outcome"],"mesh_terms":["Imatinib Mesylate","Dasatinib","Adult","Antineoplastic Agents","Humans","India","Retrospective Studies","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Leukemia, Myeloid, Chronic-Phase","Treatment Outcome","Protein Kinase Inhibitors"],"keywords":["Medicine","Dasatinib","Myeloid leukemia","Internal medicine","Oncology","Imatinib","Lower Dose Dasatinib"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-27T12:02:32.432666Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}